1
Nahum Sonenberg, Isaac Edery, Michael Altmann: Bifunctional protein for the isolation of capped mRNA. McGill University, Dressler Goldsmith Shore Sutker & Milnamow, June 15, 1993: US05219989 (21 worldwide citation)

A protein comprising at least a first functional site having the ability to bind the cap structure of mRNA and a second functional site having the ability to bind a solid support matrix in such a manner as to allow the first functional site to be immobilized and still remain functionally accessible ...


2
Martin Sumner Smith, Richard W Barnett, Lorne S Reid, Nahum Sonenberg: Peptide-based inhibitors of HIV replication. Allelix Biopharmaceuticals, Foley & Lardner, July 8, 1997: US05646120 (16 worldwide citation)

Described herein are oligopeptides useful to inhibit replication in virally infected individuals. In a preferred embodiment of the invention, the oligopeptide is a D-arginine nonamer having N- and C-terminal protecting groups, which, at a 5 uM concentration, exhibits greater than 95% inhibition of H ...


3
Nahum Sonenberg, Arnim Pause, Joe B Harford, Vincent J Miles: Methods of screening for non-hormone compounds which effect modulation of polypeptide translation. McGill University, Ribogene, Pennie & Edmonds, February 23, 1999: US05874231 (13 worldwide citation)

Method for screening for a non-hormone agent potentially useful to treat a hormone disorder. The method involves contacting a potential agent with a system containing a cellular component and a translation factor. The component and factor interact with one another in an intact normal cell in a manne ...


4
Martin Sumner Smith, Richard W Barnett, Lorne S Reid, Nahum Sonenberg: Peptide-based inhibitors of HIV replication. Allex Biopharmaceuticals, Foley & Lardner, August 4, 1998: US05789531 (8 worldwide citation)

Described herein are oligopeptides useful to inhibit replication in virally infected individuals. In a preferred embodiment of the invention, the oligopeptide is a D-arginine nonamer having N- and C-terminal protecting groups, which, at a 3 uM concentration, exhibits greater than 95% inhibition of H ...


5
Nahum Sonenberg, Michael G Katze, Sophie Roy, Antonis E Koromilas, Glen H Barber: Anti-tumor agent assay using PKR. McGill University, University of Washington, Pennie & Edmonds, September 23, 1997: US05670330 (8 worldwide citation)

A method of screening human tissue for the presence of neoplastic cells, by determining the activity of PKR, P58 of anti-P58 in test cells being screened, and identifying candidate neoplastic cells on the basis of subnormal PKR, P58, or anti-P58 activity. The activities may be determined directly by ...


6
Nahum Sonenberg, Arnim Pause, Joe B Harford, Vincent J Miles: Methods for treating hormone disorders. Questcor Pharmaceuticals, Mc Gill University, Pennie & Edmonds, June 25, 2002: US06410715 (4 worldwide citation)

Method for screening for a non-hormone agent potentially useful to treat a hormone disorder The method involves contacting a potential agent with a system containing a cellular component and a translation factor. The component and factor interact with one another in an intact normal cell in a manner ...


7
Stephen K Burley, Nahum Sonenberg, Joseph Marcotrigiano, Anne Claude Gingras: Crystal of a protein-ligand complex containing an N-terminal truncated eIF4E, and methods of use thereof. The Rockefeller University, McGill University, Klauber & Jackson, February 16, 1999: US05872011 (3 worldwide citation)

A detailed three-dimensional structure for the least abundant of the general translation initiation factors in eukaryotes, eIF4E, complexed with a ligand is disclosed. The novel N-terminal truncated eIF4Es which were constructed so as to omit a significant portion of the flexible N-terminal tail of ...


8
John C Bell, Nahum Sonenberg, David F Stojdl, Earl G Brown, Harold L Atkins, Ricardo M Marius, Brian D Lichty, Shane B Knowles: Oncolytic virus. Wellstat Biologics Corporation, Douglas A Golightly, April 3, 2012: US08147822 (1 worldwide citation)

The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differen ...


9
Stephen K Burley, Nahum Sonenberg, Joseph Marcotrigiano, Anne Claude Gingras: Crystal of a protein-ligand complex containing an N-terminal truncated eIF4E, and methods of use thereof. The Rockefeller University, McGill University, Klauber & Jackson, February 1, 2000: US06020162

A detailed three-dimensional structure for the least abundant of the general translation initiation factors in eukaryotes, eIF4E, complexed with a ligand is disclosed. The novel N-terminal truncated eIF4Es which were constructed so as to omit a significant portion of the flexible N-terminal tail of ...


10
Nahum Sonenberg, Arnim Pause, Joe B Harford, Vincent J Miles: Methods for treating hormone disorders. RiboGene, McGill University, Pennie & Edmonds, August 29, 2000: US06111077

Method for screening for a non-hormone agent potentially useful to treat a hormone disorder The method involves contacting a potential agent with a system containing a cellular component and a translation factor. The component and factor interact with one another in an intact normal cell in a manner ...